Search results for "TYR"

showing 10 items of 2017 documents

Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine.

2013

This study was aimed to evaluate the involvement of CB2 cannabinoid receptors (CB2r) in the rewarding, reinforcing and motivational effects of nicotine. Conditioned place preference (CPP) and intravenous self-administration experiments were carried out in knockout mice lacking CB2r (CB2KO) and wild-type (WT) littermates treated with the CB2r antagonist AM630 (1 and 3 mg/kg). Gene expression analyses of tyrosine hydroxylase (TH) and α3- and α4-nicotinic acetylcholine receptor subunits (nAChRs) in the ventral tegmental area (VTA) and immunohistochemical studies to elucidate whether CB2r colocalized with α3- and α4-nAChRs in the nucleus accumbens and VTA were performed. Mecamylamine-precipitat…

MaleNicotinemedicine.medical_treatmentNicotinaRecompensa (Psicologia)Self AdministrationPharmacologyNucleus accumbensNucleus AccumbensNicotineReceptor Cannabinoid CB2MiceRewardCannabinoides -- ReceptorsmedicineAnimalsAcetylcholine receptorPharmacologyMice KnockoutTyrosine hydroxylaseVentral Tegmental Areamedicine.diseaseConditioned place preferenceSubstance Withdrawal SyndromeVentral tegmental areaPsychiatry and Mental healthmedicine.anatomical_structureNicotine withdrawalConditioning OperantOriginal ArticleCannabinoidPsychologyReinforcement Psychologymedicine.drugNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
researchProduct

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

2010

Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); …

MaleNitric Oxide Synthase Type IIlcsh:ChemistryUbiquitinNeurotoxinlcsh:QH301-705.5Receptor Notch3SpectroscopyNeuronsReceptors NotchbiologyGlial fibrillary acidic proteinMicrofilament ProteinsGeneral MedicineComputer Science ApplicationsCell biologySubstantia NigraNitric oxide synthaseNeuroprotective Agentsmedicine.anatomical_structureBiochemistryNeurogliaNeurogliaMethylhydrazinesneuroimmunological biomarkersTyrosine 3-Monooxygenasesmall moleculeSubstantia nigraParkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small moleculeNeuroprotectionArticleCatalysisInorganic ChemistryGlial Fibrillary Acidic ProteinmedicineAnimalsParkinson Disease SecondaryRats WistarPhysical and Theoretical ChemistryOxidopamineMolecular BiologyTyrosine hydroxylase6-OHDA modelCalcium-Binding ProteinsmildronateOrganic ChemistryCorpus StriatumRatslcsh:Biology (General)lcsh:QD1-999nervous systemParkinson’s diseasebiology.proteinBiomarkersInternational Journal of Molecular Sciences
researchProduct

GABAergic basal forebrain afferents innervate selectively GABAergic targets in the main olfactory bulb

2010

In this work we have analyzed the targets of the GABAergic afferents to the main olfactory bulb originating in the basal forebrain of the rat. We combined anterograde tracing of 10 kD biotinylated dextran amine (BDA) injected in the region of the horizontal limb of the diagonal band of Broca that projects to the main olfactory bulb, with immunocytochemical detection of GABA under electron microscopy or vesicular GABA transporter (vGABAt) under confocal fluorescent microscopy. GABAergic afferents were identified as double labeled BDA-GABA boutons. Their targets were identified by their ultrastructure and GABA content. We found that GABAergic afferents from the basal forebrain were distribute…

MaleOlfactory systemVesicular Inhibitory Amino Acid Transport ProteinsPeriglomerular cellOlfactionBiologyProsencephalonNeural PathwaysmedicineAnimalsNeurons AfferentRats Wistargamma-Aminobutyric AcidBasal forebrainGeneral NeuroscienceOlfactory tubercleGranule cellOlfactory BulbRatsOlfactory bulbNeuroanatomical Tract-Tracing Techniquesmedicine.anatomical_structurenervous systemGABAergicFemaleNeuroscienceNeuroscience
researchProduct

Parvalbumin-containing interneurons do not innervate granule cells in the olfactory bulb

2001

Combining pre-embedding parvalbumin immunostaining and post-embedding immunogold detection of GABA in the olfactory bulb, we investigated whether the parvalbumin-containing GABAergic interneurons of the external plexiform layer exclusively innervate principal cells, or whether they also establish inhibitory synapses upon GABAergic local neurons such as granule cells. Our results demonstrate that the parvalbumin-containing cells do not contact GABAergic interneurons in the neuropil of the external plexiform layer. On the contrary, their postsynaptic elements were always non-GABAergic principal cells. Although classically it has been accepted that the interneurons of the external plexiform la…

MaleOlfactory systemgenetic structuresInterneuronInhibitory postsynaptic potentialInterneuronsPostsynaptic potentialNeural PathwaysNeuropilmedicineAnimalsRats WistarMicroscopy Immunoelectrongamma-Aminobutyric Acidbiologymusculoskeletal neural and ocular physiologyGeneral NeuroscienceOlfactory BulbRatsOlfactory bulbSmellParvalbuminsmedicine.anatomical_structurenervous systemSynapsesbiology.proteinGABAergicNeuroscienceParvalbuminNeuroreport
researchProduct

Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell t…

2012

Based on molecular aberrations, in particular the NPM1 mutation (NPM1(mut)) and the FLT3 internal tandem duplication (Flt3-ITD), prognostic subgroups have been defined among patients with acute myeloid leukemia with normal karyotype. Whereas these subgroups are known to play an important role in outcome in first complete remission, and also in the indication for allogeneic stem cell transplantation, data are limited on their role after transplantation in advanced disease. To evaluate the role of molecular subgroups of acute myeloid leukemia with normal karyotype after allogeneic stem cell transplantation beyond first complete remission, we analyzed the data from 141 consecutive adults (medi…

MaleOncologyTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantation0302 clinical medicineRecurrenceAntineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationNuclear ProteinsMyeloid leukemiaInduction ChemotherapyHematologyMiddle Aged3. Good healthFludarabineTreatment OutcomeLeukemia Myeloid030220 oncology & carcinogenesisAcute DiseaseFemaleNucleophosminmedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationAdolescentPrimary Induction FailureKaryotypeDisease-Free SurvivalYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantation HomologousAgedSalvage Therapybusiness.industryMinimal residual diseaseSurgeryTransplantationfms-Like Tyrosine Kinase 3Multivariate AnalysisMutationTransplantation ConditioningOriginal Articles and Brief ReportsbusinessFollow-Up Studies030215 immunology
researchProduct

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

2006

The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy.We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events.The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best …

MaleOncologymedicine.medical_specialtyFusion Proteins bcr-ablAntineoplastic AgentsKaplan-Meier EstimateChronic phase chronic myelogenous leukemiaDisease-Free SurvivalPiperazineschemistry.chemical_compoundLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsOmacetaxine mepesuccinatemedicineHumansneoplasmsbusiness.industryPonatinibCytarabineInterferon-alphaMyeloid leukemiaImatinibGeneral MedicineProtein-Tyrosine KinasesSurvival AnalysisSurvival RateDasatinibPyrimidinesTreatment OutcomeImatinib mesylatechemistryNilotinibBenzamidesImmunologyImatinib MesylateFemalebusinessFollow-Up Studiesmedicine.drugNew England Journal of Medicine
researchProduct

Functional Synaptic Projections onto Subplate Neurons in Neonatal Rat Somatosensory Cortex

2002

Subplate neurons (SPn) play an important role in the formation of thalamocortical connections during early development and show glutamatergic and GABAergic spontaneous synaptic activity. We characterized these synaptic inputs by performing whole-cell recordings from SPn in somatosensory cortical slices of postnatal day 0-3 rats. At -70 mV, electrical stimulation of the thalamocortical afferents elicited in 68% of the SPn a monosynaptic CNQX-sensitive postsynaptic current (PSC). These fast PSCs were mediated by AMPA receptors, because they were prolonged by cyclothiazide and blocked by GYKI 52466. On membrane depolarization, thalamocortical stimulation elicited in 50% of the cells an additio…

MalePatch-Clamp TechniquesAction PotentialsStimulationAMPA receptorBiologyIn Vitro TechniquesSomatosensory systemReceptors N-Methyl-D-AspartateMembrane PotentialsGABA AntagonistsThalamusSubplatemedicineAnimalsReceptors AMPAARTICLERats Wistargamma-Aminobutyric AcidNeuronsAfferent PathwaysGeneral NeuroscienceLysineCell MembraneExcitatory Postsynaptic PotentialsDepolarizationSomatosensory CortexReceptors GABA-AElectric StimulationRatsmedicine.anatomical_structurenervous systemAnimals NewbornSynapsesGABAergicNMDA receptorCyclothiazideNeuroscienceExcitatory Amino Acid Antagonistsmedicine.drug
researchProduct

14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt–Jakob disease measured using capture assay able to detect low lev…

2002

Abstract A protein capture assay was used to measure 14-3-3 (γ-isoform) in the cerebrospinal fluid (CSF) of patients with either variant or sporadic Creutzfeldt–Jakob disease (CJD). The results were compared with those obtained using Western blotting. Elevated levels of 14-3-3γ were found in 58% of variant CJD (vCJD) patients and 82% of sporadic CJD (spCJD) patients using the protein capture assay. Using a Western blotting technique, the presence of CSF 14-3-3γ was detected in 58% of vCJD patients and in 89% of spCJD patients. When the results from the protein capture assay and the Western blot were combined, 14-3-3γ was detected in 77% of vCJD patients and in 91% of spCJD patients. These r…

MalePathologymedicine.medical_specialtyTyrosine 3-MonooxygenaseAmino Acid MotifsBlotting WesternStatistics as TopicCreutzfeldt-Jakob SyndromeDiagnosis DifferentialCerebrospinal fluidDegenerative diseaseWestern blotPredictive Value of Testsmental disordersmedicineHumans14-3-3 proteinAgedNeuronsmedicine.diagnostic_testSporadic CJDbusiness.industryGeneral NeuroscienceBrainReproducibility of ResultsSporadic Creutzfeldt-Jakob diseaseMiddle Agedmedicine.diseaseVirologyUp-Regulationnervous system diseasesVariant cjdBlot14-3-3 ProteinsBiological AssayFemalebusinessBiomarkersNeuroscience Letters
researchProduct

Differences among young adults, adults and elderly chronic myeloid leukemia patients

2014

Abstract BACKGROUND: The incidence of chronic myeloid leukemia (CML) increases with age, but it is unclear how the characteristics of the disease vary with age. In children, where CML is very rare, it presents with more aggressive features, including huge splenomegaly, higher cell count and higher blast cell percentage. PATIENTS AND METHODS: To investigate if after childhood the disease maintains or loses these characteristics of aggressiveness, we analyzed 2784 adult patients, at least 18 years old, registered by GIMEMA CML WP over a 40-year period. RESULTS: Young adults (YAs: 18-29 years old) significantly differed from adults (30-59 years old) and elderly patients (at least 60 years old)…

MalePediatricsHost responseBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Oncology; HematologyTyrosine kinase inhibitorDiseaseAntineoplastic AgentTyrosin kinase inhibitorProtein-Tyrosine Kinasehemic and lymphatic diseases80 and overAge FactorProspective StudiesYoung adultChronicBCR-ABLAged 80 and overLeukemiaIncidence (epidemiology)Chronic myeloid leukemiaAge FactorsMyeloid leukemiaHematologyMiddle AgedProtein-Tyrosine KinasesPrognosisLeukemiaOncologybcr-abl1FemaleBCR-ABL; chronic myeloid leukemia; prognosis; tyrosine kinase inhibitors; young adultsHumanAdultyoung adultsmedicine.medical_specialtyPrognosiProtein Kinase InhibitorAntineoplastic Agentschronic myeloid leukemia; bcr-abl1; Tyrosin kinase inhibitor; prognosis; young adultsNOYoung Adultchronic myeloid leukemiaLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young AdultProtein Kinase InhibitorsAgedTyrosine kinase inhibitorsAdult patientsbusiness.industrymedicine.diseaseClinical trialBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Hematology; OncologyProspective StudieBCR-ABL; Chronic myeloid leukemia; Prognosis; Tyrosine kinase inhibitors; Young adults; Adult; Age Factors; Aged; Aged 80 and over; Antineoplastic Agents; Female; Humans; Leukemia Myelogenous Chronic BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Spleen; Splenomegaly; Young Adult; Medicine (all); Hematology; OncologyImmunologySplenomegalyBCR-ABL PositiveBCR-ABL chronic myeloid leukemia prognosis tyrosine kinase inhibitors young adultsprognosisbusinessSpleenYoung adultsMyelogenous
researchProduct

Modulation of in vivo GABA-evoked responses by nitric oxide-active compounds in the globus pallidus of rat.

2012

Nitric oxide (NO) is a gaseous molecule acting as a messenger in both the peripheral and the central nervous systems. NO affects synaptic activity by modulating neurotransmitter release and/or receptor function. We previously observed that NO-active compounds modify the bioelectric activity of basal ganglia (BG) units. In this study, we applied microiontophoresis to extracellular in vivo recordings to investigate the effect of NO-active compounds on GABA-evoked responses in the globus pallidus (GP) of anesthetized rats. The changes induced by NO-active drugs on the GABA-induced inhibition were used as indicators of NO modulation. The response to GABA release was tested on recorded GP neuron…

MalePharmacologyBiologyNeurotransmissionGlobus PallidusNitric OxideSettore BIO/09 - FisiologiaSynaptic Transmissiongamma-Aminobutyric acidNitric oxidechemistry.chemical_compoundIn vivomedicineAnimalsRats WistarNeurotransmitterEvoked PotentialsBiological Psychiatrygamma-Aminobutyric AcidNeuronsNitric oxide Basal ganglia Globus pallidus Microiontophoresis GABA transmissionIontophoresisRatsNitric oxide synthaseElectrophysiologyPsychiatry and Mental healthElectrophysiologyGlobus pallidusnervous systemNeurologychemistrybiology.proteinNeurology (clinical)Neurosciencemedicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct